Last reviewed · How we verify
Cohort 1, GNR-084
At a glance
| Generic name | Cohort 1, GNR-084 |
|---|---|
| Also known as | Anti-CD19/CD3 antibody |
| Sponsor | AO GENERIUM |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cohort 1, GNR-084 CI brief — competitive landscape report
- Cohort 1, GNR-084 updates RSS · CI watch RSS
- AO GENERIUM portfolio CI